The Latin America, Middle East and Africa Infertility Drugs Market should witness market growth of 8.8% CAGR during the forecast period (2022-2028).
Hormonal treatment is used during ovulation induction to encourage the release of eggs or ovulation. Historically, these medications were developed to help women who had irregular menstrual periods or who could not ovulate naturally. Creating a single, healthy egg was the aim.
Increased odds of conception were achieved by using ovulation induction to boost the number of eggs maturing in a single cycle. Injectable drugs were the original treatment agents, which were initially employed for in vitro fertilization (IVF) and afterward for less complicated procedures. These medications come with a higher chance of multiple pregnancies, ovarian hyperstimulation, and a higher price tag and time commitment.
Ovulation induction and intrauterine insemination are usually coupled in ovulatory females. Ovulation induction shouldn't proceed until a comprehensive assessment has been completed. Prior to using fertility medications to induce ovulation, hormone problems such as thyroid dysfunction should be addressed.
Nearly 60% of all instances of infertility are attributed to male factors, and 30-50% of these cases are still idiopathic. About 22.6% of males in the area of the Middle East and North Africa (MENA) who are of reproductive age have male infertility. Numerous variables, such as endocrine disruption, exposure to chemicals, lifestyle choices, and genetic and epigenetic changes, contribute to male infertility. Due to the high frequency of male infertility in the MENA area, it is crucial to investigate the effect, as a genetic aberration is a major factor in the pathogenesis of male infertility. As a result, the market for infertility drugs in LAMEA is growing due to the region's increasing infertility cases.
The Brazil market dominated the LAMEA Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $81.3 million by 2028. The Argentina market is showcasing a CAGR of 9.4% during (2022-2028). Additionally, The UAE market would register a CAGR of 8.5% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Hormonal treatment is used during ovulation induction to encourage the release of eggs or ovulation. Historically, these medications were developed to help women who had irregular menstrual periods or who could not ovulate naturally. Creating a single, healthy egg was the aim.
Increased odds of conception were achieved by using ovulation induction to boost the number of eggs maturing in a single cycle. Injectable drugs were the original treatment agents, which were initially employed for in vitro fertilization (IVF) and afterward for less complicated procedures. These medications come with a higher chance of multiple pregnancies, ovarian hyperstimulation, and a higher price tag and time commitment.
Ovulation induction and intrauterine insemination are usually coupled in ovulatory females. Ovulation induction shouldn't proceed until a comprehensive assessment has been completed. Prior to using fertility medications to induce ovulation, hormone problems such as thyroid dysfunction should be addressed.
Nearly 60% of all instances of infertility are attributed to male factors, and 30-50% of these cases are still idiopathic. About 22.6% of males in the area of the Middle East and North Africa (MENA) who are of reproductive age have male infertility. Numerous variables, such as endocrine disruption, exposure to chemicals, lifestyle choices, and genetic and epigenetic changes, contribute to male infertility. Due to the high frequency of male infertility in the MENA area, it is crucial to investigate the effect, as a genetic aberration is a major factor in the pathogenesis of male infertility. As a result, the market for infertility drugs in LAMEA is growing due to the region's increasing infertility cases.
The Brazil market dominated the LAMEA Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $81.3 million by 2028. The Argentina market is showcasing a CAGR of 9.4% during (2022-2028). Additionally, The UAE market would register a CAGR of 8.5% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Scope of the Study
By End-user
- Women
- Men
By Distribution Channel
- Hospital Pharmacy
- Specialty & Retail Pharmacy
- Online Pharmacy
By Drug Class
- Gonadotropins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Infertility Drugs Market, by End User
1.4.2 LAMEA Infertility Drugs Market, by Distribution Channel
1.4.3 LAMEA Infertility Drugs Market, by Drug Class
1.4.4 LAMEA Infertility Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Infertility Drugs Market by End-user
3.1 LAMEA Women Market by Country
3.2 LAMEA Men Market by Country
Chapter 4. LAMEA Infertility Drugs Market by Distribution Channel
4.1 LAMEA Hospital Pharmacy Market by Country
4.2 LAMEA Specialty & Retail Pharmacy Market by Country
4.3 LAMEA Online Pharmacy Market by Country
Chapter 5. LAMEA Infertility Drugs Market by Drug Class
5.1 LAMEA Gonadotropins Market by Country
5.2 LAMEA Aromatase Inhibitors Market by Country
5.3 LAMEA Selective Estrogen Receptor Modulators (SERMs) Market by Country
5.4 LAMEA Dopamine Agonists Market by Country
5.5 LAMEA Others Market by Country
Chapter 6. LAMEA Infertility Drugs Market by Country
6.1 Brazil Infertility Drugs Market
6.1.1 Brazil Infertility Drugs Market by End-user
6.1.2 Brazil Infertility Drugs Market by Distribution Channel
6.1.3 Brazil Infertility Drugs Market by Drug Class
6.2 Argentina Infertility Drugs Market
6.2.1 Argentina Infertility Drugs Market by End-user
6.2.2 Argentina Infertility Drugs Market by Distribution Channel
6.2.3 Argentina Infertility Drugs Market by Drug Class
6.3 UAE Infertility Drugs Market
6.3.1 UAE Infertility Drugs Market by End-user
6.3.2 UAE Infertility Drugs Market by Distribution Channel
6.3.3 UAE Infertility Drugs Market by Drug Class
6.4 Saudi Arabia Infertility Drugs Market
6.4.1 Saudi Arabia Infertility Drugs Market by End-user
6.4.2 Saudi Arabia Infertility Drugs Market by Distribution Channel
6.4.3 Saudi Arabia Infertility Drugs Market by Drug Class
6.5 South Africa Infertility Drugs Market
6.5.1 South Africa Infertility Drugs Market by End-user
6.5.2 South Africa Infertility Drugs Market by Distribution Channel
6.5.3 South Africa Infertility Drugs Market by Drug Class
6.6 Nigeria Infertility Drugs Market
6.6.1 Nigeria Infertility Drugs Market by End-user
6.6.2 Nigeria Infertility Drugs Market by Distribution Channel
6.6.3 Nigeria Infertility Drugs Market by Drug Class
6.7 Rest of LAMEA Infertility Drugs Market
6.7.1 Rest of LAMEA Infertility Drugs Market by End-user
6.7.2 Rest of LAMEA Infertility Drugs Market by Distribution Channel
6.7.3 Rest of LAMEA Infertility Drugs Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Bayer AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Acquisition and Mergers:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Merck & Co., Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Ferring Holdings SA
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research and Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Organon & Co.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.10. Mankind Pharma Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Product Launches and Product Expansions:
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Methodology
LOADING...
